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The immunopathogenesis of severe dengue is poorly understood, but there is concern that induction of cross-
reactive nonneutralizing antibodies by infection or vaccination may increase the likelihood of severe disease
during a subsequent infection. We generated a total of 63 new human monoclonal antibodies to compare the
B-cell response of subjects who received the National Institutes of Health live attenuated dengue vaccine
rDEN1Δ30 to that of subjects following symptomatic primary infection with DENV1. Both infection and vacci-
nation induced serum neutralizing antibodies and DENV1-reactive peripheral blood B cells, but the magnitude
of induction was lower in vaccinated individuals. Serotype cross-reactive weakly neutralizing antibodies domi-
nated the response in both vaccinated and naturally infected subjects. Antigen specificities were very similar,
with a slightly greater percentage of antibodies targeting E protein domain I/II than domain III. These data
shed light on the similarity of human B-cell response to live attenuated DENV vaccine or natural infection.
Keywords. human; B cells; hybridomas; dengue virus; antibodies; antibody-dependent enhancement; neutrali-
zation.
Dengue viruses (DENVs) have become the most
common arboviral pathogen worldwide. There are no
licensed dengue vaccines available. The 4 DENV sero-
types, denoted DENV1–4, are all capable of causing
symptomatic disease that ranges in severity from an un-
differentiated febrile illness to life-threatening hemor-
rhagic fever and shock. The most recent World Health
Organization estimates suggest that 50–100 million
DENV infections occur each year, resulting in >20 000
deaths [1–3], most often in children. The risk of devel-
oping severe disease is lower during the first infection
with DENV (primary infection) than during a second
infection with a different serotype of DENV (secondary
infection) [4]. The most widely accepted model of the
pathogenesis of severe dengue proposes that an initial
infection with DENV occurs and induces serotype–
cross-reactive antibodies. This event is followed, in
most cases years later, with a second infection by a dif-
ferent serotype, during which time preexisting cross-re-
active antibodies form nonneutralized DENV-antibody
complexes that allow the virus to enter Fc receptor–
expressing cells more efficiently. This mechanism
might result in increased viral replication, viremia, and
subsequent release of cytokines and vasoactive media-
tors that increase vascular permeability. This process has
been termed antibody-dependent enhancement (ADE)
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of infection and has been demonstrated using cells in culture, in
animal models, and, to some extent, in humans.
DENV belongs to the Flaviviridae family and displays
pseudo-icosahedral symmetry, with 180 copies of the envelope
(E) glycoprotein and 180 copies of the premembrane/mem-
brane (prM/M) protein in the lipid bilayer membrane. The E
glycoprotein monomer possesses 3 principal domains, desig-
nated domain I (DI), DII, and DIII. Panels of human monoclo-
nal antibodies (mAbs) recently generated by several groups
have demonstrated that the human response targets both E and
prM proteins and is made up largely of serotype–cross-reactive
weakly neutralizing antibodies [5–9]. Only a small percentage
of antibodies directed against surface-exposed epitopes are sero-
type-specific or neutralizing at a concentration of <0.5 µg/mL [5].
DENV immune serum depletion studies have shown that the
antibodies responsible for serum neutralizing activity in
humans following DENV infection do not target E protein
DIII, as was previously thought, but target other areas, such
as complex epitopes existing only on the assembled virion par-
ticle [6, 10]. Furthermore, the detailed mapping of a strongly
neutralizing virion-only binding antibody, in complex with
DENV1, was recently published using cryoelectron microscopy [11].
Considered together, these studies establish a conceptual foun-
dation that we can use to evaluate the human antibody re-
sponse to DENV vaccination.
For a dengue vaccine to be successful, there is consensus that
it must protect against all 4 serotypes, thus almost certainly re-
quiring a tetravalent vaccine formulation. This goal creates a
unique challenge. If protection is not achieved for ≥1 DENV
serotype in an individual, cross-reactive nonneutralizing anti-
bodies directed at other serotypes could bind the infecting
virus, potentially resulting in enhanced disease severity. With
this in mind, several vaccine strategies are currently under de-
velopment, including live attenuated virus vaccines, killed or
inactivated virus preparations, viral vectored constructs, DNA
plasmid vaccines, and protein subunit vaccines [12, 13]. A
recent publication described data acquired from a phase IIb
clinical trial conducted in Thailand of ChimeriVax (Sanofi
Pasteur), a live attenuated tetravalent dengue-yellow fever 17D
chimeric virus vaccine [14, 15]. The overall efficacy of the
vaccine was determined to be only 30.2%, with no vaccine-
induced ADE detected, although the follow-up duration was
only 13 months.
An additional live attenuated vaccine candidate being tested
in clinical trials uses the National Institutes of Health (NIH)
rDENΔ30 platform. The rDEN4Δ30 virus was first engineered
through deletion of a 30-nucleotide segment of the 3′ untrans-
lated region [16] and was later found to be safe and immuno-
genic in 3 phase I clinical trials [17–19]. The Δ30 mutation
then was introduced into the homologous region of DENV1
Western Pacific strain, and the resulting mutant virus was des-
ignated rDEN1Δ30. The live attenuated rDEN1Δ30 vaccine
candidate subsequently was tested in rhesus monkeys [20] and
then evaluated in a phase I clinical trial [21]. A single dose was
well tolerated by vaccinees and elicited a >4-fold rise in serum
neutralizing antibody titers. A second trial was performed to
test whether the humoral immune response could be boosted
by a second dose of rDEN1Δ30 [22]. The second dose did not
induce a significant rise in serum neutralizing antibody titers,
suggesting that the primary vaccination induced sterilizing
humoral immunity for vaccine virus [22]. An investigational
tetravalent dengue vaccine currently moving into phase II eval-
uation builds on these results, using rDEN1Δ30 as one of the
components [23].
In the present study, we compared in detail the memory B-
cell response in subjects who received the NIH live attenuated
rDEN1Δ30 vaccine to that of subjects following natural
DENV1 infection. We generated a total of 63 human hybrid-
omas to DENV1 and characterized the function of the encoded
DENV-reactive monoclonal antibodies in detail.
METHODS
Human Subjects and Peripheral Blood Cell Isolation
Serum and peripheral blood mononuclear cells (PBMCs) were
obtained 28 days following a second vaccine dose (7 months
after the first dose) from subjects who received the live attenu-
ated rDEN1Δ30 vaccine; informed consent was obtained from
all subjects [22]. We also identified a panel of subjects in North
Carolina or California who had acquired DENV infection natu-
rally by screening volunteers with suspected symptomatic expo-
sure during past travel to dengue-endemic regions, with
informed consent received from all subjects. Subjects were con-
firmed to have had primary DENV1 infection by testing their
serum for the presence of antibodies that neutralized each of
the DENV serotypes. PBMCs were isolated by density gradient
separation on Ficoll. The cells were cryopreserved immediately
and stored in liquid nitrogen until study. The protocol for re-
cruiting and collecting blood samples from subjects was ap-
proved by the institutional review boards of the University of
North Carolina at Chapel Hill and the La Jolla Institute for
Allergy and Immunology.
Viruses
DENV1 WestPac-74, DENV2 S-16803, DENV3 CH-53489,
and DENV4 TVP-360 virus strains, provided by Dr Robert
Putnak (Walter Reed Army Institute of Research, Silver Spring,
MD) were used in the present study for both binding enzyme-
linked immunosorbent assay (ELISA) and neutralization
assays. Virus-containing cell culture supernatant used in virus-
capture ELISA was prepared in C6/36 mosquito cells grown in
complete minimum essential medium (catalog no. 51985-034,
Gibco).
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Generation of Human Hybridomas
Previously cryopreserved samples were thawed rapidly in a 37°
C water bath and washed prior to transformation with Epstein-
Barr virus (EBV), CpG, and additional supplements as de-
scribed previously [5]. Cultures were incubated at 37°C with 5%
CO2 for 10 days prior to screening for DENV1-reactive cell
lines with ELISA (the capture ELISA method is described
below). The minimal frequency of DENV1-reactive B cells was
estimated on the basis of the number of wells with DENV1-
reactive supernatants as compared to the total number of lym-
phoblastoid cell line colonies in the transformation plates, as
follows: [number of wells with DENV1-reactive supernatants]/
[number of LCL colonies in the plate]. Cells from wells with su-
pernatants reacting in the DENV1 capture ELISA were expand-
ed prior to cytofusion with HMMA2.5 nonsecreting myeloma
cells, as previously described [5]. Following cytofusion, hybrid-
omas were selected for growth in HAT medium containing
ouabain and were biologically cloned.
MAb Production and Purification
Wells containing hybridomas producing DENV1-reactive anti-
bodies were cloned biologically by 3 rounds of limiting dilution
plating or by use of a ClonePix device (Molecular Devices) in
accordance with the manufacturer’s recommendations. Once
clonal, the cell lines were used to produce mAb immunoglobu-
lin G (IgG) in cell supernatants, using serum-free medium, fol-
lowed by protein G column purification.
Virus and Recombinant Protein ELISA
For virus-capture ELISA, purified mouse mAb 4G2 (1 mg/mL
stock) prepared in carbonate binding buffer (dilution, 1:1000)
was used to coat 384 well ELISA plates at 25 µL per well (Nunc
242 757) and incubated overnight at 4°C. After blocking for 1
hour, plates were washed 5 times with phosphate-buffered
saline (PBS), and 50 µL/well of DENV-containing culture su-
pernatant from infected C6/36 cell culture monolayers was
added (using the 4 strains listed above). Plates then were
washed 10 times with PBS, and 5 µL of purified human mono-
clonal antibody (1 µg/µL) was added into 25 µL/well of block-
ing solution. Plates were incubated at room temperature for 1
hour prior to washing 5 times with PBS. Secondary antibody
(goat anti-human Fc; catalog no. W99008A, Meridian Life
Science) was added at a dilution of 1:5000 to blocking solution,
using 25 µL/well, and plates again were incubated at room tem-
perature for 1 hour. After the plates were washed 5 times with
PBS, phosphatase substrate solution (1 mg/mL phosphatase
substrate in 1 M Tris aminomethane; catalog no. S0942, Sigma)
was added at 25 µL/well, and plates were incubated at room
temperature for 2 hours before reading the optical density at
405 nm on a Biotec plate reader.
For recombinant protein capture ELISA that used E protein
or prM protein constructs, purified mouse anti-Strep-tag II
mAb (catalog no. IBA 2-1517-001, StrepMAB-Immo; 1 mg/mL
stock) prepared in carbonate binding buffer (dilution, 1:500)
was used to coat 384-well ELISA plates at 25 µL/well (Nunc
242 757) and incubated at 4°C overnight. After plates were
exposed to blocking solution for 1 hour, they were washed 5
times with PBS, and 50 µL of recombinant protein construct
containing culture supernatant (cultured in insect cells) was
added (production of recombinant proteins is described in
Supplementary Materials and Methods). Plates then were
washed 10 times with PBS, and 5 µL of purified human mono-
clonal antibody (1 µg/µL) was added into 25 µL/well of block-
ing solution. All other steps were performed as described above
for the virus-capture ELISA.
Neutralization Assay
Serum neutralization assays were performed as described else-
where, using a 50% plaque reduction neutralization test
(PRNT50) [17]. Virus strains used in the assay were as follows:
DENV1, strain WestPac-74; DENV2, strain New Guinea C;
DENV3, strain Sleman; and DENV4, strain 814 669.
The neutralizing potency of monoclonal antibodies was mea-
sured using a flow cytometry–based neutralization assay with
the U937 human monocytic cell line stably transfected with
DC-SIGN, as previously described [24].
ADE Assays
The ability of antibodies to enhance DENV infection was mea-
sured using U937 cells at a single dilution (concentration, 1 µg/
mL). Because these Fc receptor cells do not have DENV virus
attachment factor, the cells are only susceptible to infection in
the presence of DENV-reactive antibodies. The assay was per-
formed as described in detail previously [5]. ADE activity was
expressed as the percentage increase of infected cells in the
DENV-reactive antibody–treated sample as compared to the
sample treated with a control antibody.
Statistical Analysis
Prism, version 5.0 (GraphPad), was used for data analysis. For
statistical comparisons between 2 groups of data, the Student t
test was used. A P value of ≤ .05 was considered a statistically
significant difference.
RESULTS
Serum Neutralization Titers and DENV1-Reactive B-Cell
Frequencies Were Lower in Vaccinated Individuals
Twenty-two serum samples were obtained after vaccination
with rDEN1Δ30 vaccine, and 4 serum samples were obtained
after natural infection with DENV1. The times since vaccina-
tion or infection prior to serum collection are indicated in
Table 1. To compare the serum neutralization potency of
serum in vaccinated and naturally infected individuals, we per-
formed a PRNT50. Mean reciprocal serum neutralizing titers
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(±SD) in vaccinated subjects were 48 ± 48, while those in indi-
viduals with natural infection were 184 ± 92. The difference in
reciprocal serum titers was statistically significant (P=.0001;
Figure 1A).
To assess the circulating DENV1-reactive B-cell frequen-
cies, PBMCs from vaccinated or naturally infected individuals
were transformed with EBV, as described in the Methods sec-
tion. The minimal frequency of DENV1-reactive B cells was
determined for 22 PBMC samples obtained after vaccination
and for 4 PBMC samples obtained after natural infection
(Table 1). Mean frequencies (±SD) in vaccinated subjects were
800 ± 485 DENV1-reactive B cells per million circulating EBV-
transformable B cells. Naturally infected subjects had a mean
frequency (±SD) of 3870 ± 1283 DENV1-reactive B cells per
million circulating EBV-transformable B cells. The difference
in frequencies was highly statistically significant (P < .0001;
Figure 1B).
B Cells Induced by Vaccination or Natural Infection Displayed
Similar Serotype–Cross-reactivity Profiles
To compare the serotype–cross-reactivity profile of circulating
B cells induced by vaccination or natural infection, DENV1-
positive EBV-transformed B-cell culture supernatants were an-
alyzed in a virion-capture ELISA. A total of 88 DENV1-positive
B-cell culture supernatants obtained after vaccination and 148
obtained after natural infection were studied (Figure 2A). In
both groups, 59% were found to be DENV-complex reactive
(ie, they bound to all 4 DENV serotypes). DENV-subcomplex–
reactive antibodies (ie, those binding to >1 but <4 DENV sero-
types) made up the majority of the remaining supernatants
Table 1. Clinical and Serologic Characteristics of and Hybridoma Yield From Recipients of Live Attenuated Dengue Vaccine and Travel-

















31 rDEN1Δ30 vaccination 28 db 14 1/384 1 0
32 rDEN1Δ30 vaccination 28 db 31 5/384 7 1
33 rDEN1Δ30 vaccination 28 db 55 6/384 5 2
35 rDEN1Δ30 vaccination 28 db 37 13/384 8 3
36 rDEN1Δ30 vaccination 28 db 67 4/384 3 0
38 rDEN1Δ30 vaccination 28 db 19 5/384 9 1
39 rDEN1Δ30 vaccination 28 db 189 5/384 5 2
40 rDEN1Δ30 vaccination 28 db 38 14/384 9 2
41 rDEN1Δ30 vaccination 28 db 7 1/384 2 0
43 rDEN1Δ30 vaccination 28 db 63 5/384 8 0
44 rDEN1Δ30 vaccination 28 db 55 6/384 12 1
45 rDEN1Δ30 vaccination 28 db 36 17/384 9 3
46 rDEN1Δ30 vaccination 28 db 33 1/384 1 0
47 rDEN1Δ30 vaccination 28 db 38 12/384 6 3
49 rDEN1Δ30 vaccination 28 db 37 7/384 2 2
50 rDEN1Δ30 vaccination 28 db 20 4/384 1 0
52 rDEN1Δ30 vaccination 28 db 189 9/384 16 0
53 rDEN1Δ30 vaccination 28 db 39 10/384 15 2
55 rDEN1Δ30 vaccination 28 db 30 5/384 8 1
56 rDEN1Δ30 vaccination 28 db 26 1/384 1 0
57 rDEN1Δ30 vaccination 28 db 11 11/384 6 2
58 rDEN1Δ30 vaccination 28 db 20 6/384 13 1
006 Primary DENV1 infection Unknown 121c 17/384 23 2
106 Primary DENV1 infection 2 y 90c 78/768 44 29
GL10 Primary DENV1 infection 7 y 254c 71/768 34 5
GL24 Primary DENV1 infection 15 y 271c 159/1152 53 1
Abbreviations: Ab, antibody; EBV, Epstein-Barr virus; Neut50, concentration at which 50% of virus was neutralized.
a Data are estimated on the basis of the total number of EBV-transformed B-cell colony counts in the transformation plate.
b Since second vaccination.
c Titers to the heterologous DENV serotypes 2, 3, and 4, respectively, were as follows: for subject 006, 11, 5, and <5; for subject 106, 15, 13, and 11; for subject
GL10, 16, 13, and 7; and for subject GL24, 55, 30, and 10.
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tested, at 27% and 37%, in the vaccinated and naturally infected
groups, respectively. Antigen-binding specificity also was
tested, and results showed that E protein binding accounted for
43% and 72% of the antibodies obtained after vaccination and
after natural infection, respectively (Figure 2B).
We generated human hybridomas from DENV1-positive B-
cell cultures to study at a clonal level the antigen-reactivity
profiles, neutralization potency, and antibody-dependent en-
hancement properties of antibodies produced following vac-
cination and natural infection (Table 1). A total of 63
hybridomas was generated, 26 from vaccinated subjects and 37
from naturally infected subjects (Table 2). The cross-reactivity
profiles of mAbs were tested (Figure 3). Following vaccination,
all of the mAbs obtained were found to be cross-reactive: 81%
were DENV-complex reactive, while 19% were DENV-subcom-
plex reactive. Similar results were obtained following natural in-
fection, where only 1 serotype-specific mAb was identified.
B Cells Induced by Vaccination or Natural Infection Displayed
Similar Antigen-Binding Profiles
To understand the distribution of antigenic sites targeted by
the immune response to DENV1 infection or vaccination,
mAbs were tested for binding to recombinant E protein or prM
protein constructs by ELISA (Figure 4). Approximately one-
third of all the mAbs isolated were determined to bind to the pr
portion of prM protein. The other two-thirds in each group (ie,
62% following vaccination and 65% following natural infection)
were found to bind to E protein. Also, of the E protein–binding
mAbs, both groups had a greater percentage directed toward
domain I-II than to domain III. Thirty-five percent of the total
mAbs isolated following vaccination and 43% isolated follow-
ing natural infection bound to E protein domain I-II. In both
groups, the antibody response appeared to be divided roughly
equally into thirds among the prM protein, E protein domain
I-II, and E protein domain III.
Neutralization and Enhancement Characteristics of B Cells
Induced by Vaccination or Natural Infection Were Similar
The neutralizing potency of each mAb was tested against repre-
sentative viruses from each of the 4 DENV serotypes. The
results are shown in Table 2. The vast majority of mAbs from
both groups were poorly neutralizing, with a Neut50 of >10 µg/
mL. One antibody from the vaccine group and 1 from the
natural infection group showed moderate neutralizing capabili-
ty (Neut50, 1–10 µg/mL). Three mAbs, 1C19.2 (EDIII binding)
and 1L13 (prM binding) following vaccination and 1M4 (EDI-
II binding) following natural infection, were strongly neutraliz-
ing, with a Neut50 of <1.0 µg/mL (Table 3).
We also investigated the antibody-dependent infection-
enhancing properties of each mAb against viruses from each of
the 4 DENV serotypes (Table 2). At the concentration tested,
most of the mAbs showed some degree of infection enhance-
ment toward ≥1 of the DENV serotypes. The proportion of
strongly enhancing mAbs (ie, those exhibiting >25-fold en-
hancement of infection) was 18 of 26 (69%) in the vaccine
group and 15 of 37 (41%) in the natural infection group. In the
vaccine group, 69% of E protein–binding mAbs (11/16) and
70% of prM protein–binding mAbs (7/10) possessed strong in-
fection-enhancing capacity. In the natural infection group, 33%
of E protein–binding mAbs (8/24) and 54% of prM protein–
binding mAbs (7/13) enhanced infection in vitro by >25-fold
(Table 2).
Figure 1. Dengue virus serotype 1 (DENV1) reciprocal serum neutraliz-
ing antibody titers and B cell frequencies following vaccination or natural
infection. A, Fifty percent plaque reduction neutralization test assays were
performed against DENV1 on 22 serum samples obtained after vaccination
and 4 obtained after natural infection; results are shown as reciprocal
serum titers. Statistical analysis was performed using a t test. B, Frequen-
cies of circulating DENV–reactive B cells were estimated on the basis of
supernatants from Epstein-Barr virus (EBV)–transformed peripheral blood
mononuclear cell samples during clonal colony formation. Average
DENV1-reactive B-cell frequencies were 800 and 3870 per million circulat-
ing EBV-transformable B cells for vaccinated and naturally infected sub-
jects, respectively. Statistical analysis was performed using t test. The
error bars represent SDs.
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DISCUSSION
Isolation and characterization of a large panel of human mAbs
from subjects who received the NIH live attenuated vaccine
rDEN1Δ30 or subjects who were naturally infected with
DENV1 revealed a high degree of similarity in the induced
memory repertoire. Serum neutralization titers and DENV1-
reactive B-cell frequencies were lower in vaccinated individuals.
However, this observation should be interpreted with the un-
derstanding that we screened symptomatic travelers, using neu-
tralization to identify natural primary DENV1 infections, and
that live attenuated vaccination results in a clinically asymp-
tomatic infection. Thereby only subjects with robust DENV1
neutralizing antibody titers were included in the DENV1
natural infection group. In most respects, however, the human
B-cell response was similar following DENV1 vaccination or
natural infection. Results showed that the repertoire in both
groups was dominated by cross-reactive antibodies with low or
no neutralizing potency and significant potential to enhance
infectivity by Fc-mediated mechanisms. The frequency of
strongly neutralizing antibodies was similar, albeit very low,
making up only 5% of all antibodies tested. Antigen specificities
of the response also were similar, with roughly two-thirds of
antibodies targeting the E protein and one-third targeting the
prM protein.
This study demonstrates for the first time that the high fre-
quency of B cells encoding serotype–cross-reactive weakly neu-
tralizing antibodies that has been described for natural DENV
infection [5, 7–9] is also induced following live attenuated virus
vaccination. These findings are in concordance with the
concept that the DENV neutralizing activity in serum, which
likely contributes to protection against reinfection with the in-
ducing virus serotype, is determined principally by rare popula-
tions of B cells, not a collective effect of weakly neutralizing
cross-reactive populations [6]. DENV1-reactive B-cell frequen-
cies in vaccinated subjects were lower than those in naturally
infected patients, a finding that also was reflected in the serum
neutralization activities. It is possible that vaccination induces a
lower frequency of DENV-reactive memory B cells and a lower
level of secreted antibodies. Caveats about the interpretation of
these data are that collection of samples from naturally infected
donors occurred at significantly later time points than for vacci-
nees, and the DENV1 wild-type and vaccine strain antigens
were likely not identical. Another limitation of this study is
that the profile of B-cell clones described does not necessarily
predict whether protection would be afforded by the vaccine,
because vaccine efficacy can only be determined by large clini-
cal trials.
Recently, we identified a subpopulation of potently neutraliz-
ing antibodies, termed virion-only binding antibodies (because
Figure 2. Virus cross-reactivity and antigen-specificity profiles of Epstein-Barr virus (EBV)–transformed dengue virus (DENV)–reactive B-cell cultures fol-
lowing vaccination or natural infection. A, Eighty-eight DENV serotype 1 (DENV1)–positive B-cell culture supernatants obtained after vaccination (left) and
148 obtained after natural infection (right) underwent enzyme-linked immunosorbent assay for binding to heterologous DENV. DENV-complex reactive:
binding to all 4 DENV serotypes; DENV-subcomplex reactive, binding to 2 or 3 DENV serotypes; DENV-serotype specific, binding only to DENV1. B, Eighty-
eight DENV1-positive B-cell culture supernatants obtained after vaccination (left) and 148 obtained after natural infection underwent ELISA for binding to
recombinant premembrane (rPr) or E (rE) protein. Virus-only binding, B-cell culture supernatants that bound to whole virus but did not show binding to
either rPr or rE protein.
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rPr D1 D2 D3 D4 D1 D2 D3 D4
rDENV1Δ30 vaccination
32
1K12 IgG1 λ + + + + + + – – >10 >10 >10 >10 56 1 1 1
33
1C8 IgG1 κ + + + + – – – + >10 >10 >10 >10 13 31 130 15
1O21.2 IgG1 κ + + + + + + – – >10 >10 >10 >10 1 0 1 1
35
1D7.3 IgG1 λ + + + + + + – – >10 >10 >10 >10 27 9 20 1
1N23 IgG3 κ + + + – + + – – >10 >10 >10 >10 3 18 6 1
1C9 IgG1 λ + + + + – – – + >10 >10 >10 >10 15 40 54 13
38
1I23 IgG1 κ + + + – + + – – >10 >10 >10 >10 4 18 28 1
39
1O6 IgG1 κ + + + + – – – + >10 >10 >10 >10 119 67 54 15
1I15 IgG1 κ + + + + – – – + >10 >10 >10 >10 92 74 37 4
40
1C19.2 IgG1 κ + + + + + + – – 0.22 >10 >10 >10 5 1 1 1
1O10 IgG1 λ + + + + + – + – >10 >10 >10 >10 146 166 40 6
44
1J16.2 IgG1 κ + + + + + – + – >10 >10 >10 >10 97 88 26 3
45
1D7.2 IgG1 κ + + + + + – + – >10 >10 >10 >10 65 53 17 2
1L18 IgG1 λ + + + + – – – + >10 >10 >10 >10 81 60 30 6
1E8 IgG1 κ + + + + + – + – >10 >10 >10 >10 6 3 24 4
47
1C22 IgG1 λ + + + – + + – – 2.5 >10 >10 >10 3 11 10 2
1I14 IgG1 κ + + + + – – – + >10 >10 >10 >10 5 10 7 2
1E1 IgG1 κ + + + + + – + – >10 >10 >10 >10 8 8 26 4
49
1M12.2 IgG1 κ + + + + + – + – >10 >10 >10 >10 8 8 30 1
1H7 IgG1 κ + – + + – – – + >10 >10 >10 >10 13 1 13 5
53
1L13 IgG1 λ + + + + – – – + >10 >10 0.24 >10 9 15 15 9
1I7 IgG1 λ + + + + + – + – >10 >10 >10 >10 8 28 10 2
55
1P11 IgG3 λ + + + + – – – + >10 >10 >10 >10 26 23 213 4
57
1I6 IgG1 λ + + + + + – + – >10 >10 >10 >10 11 11 56 5
1D3 IgG1 κ + + + – – – – + >10 >10 >10 >10 11 11 56 5
58
1M18 IgG1 λ + + + + + – + – >10 >10 >10 >10 8 7 35 1
Primary DENV1 infection
006
1B17.2 IgG1 κ + + + + + + – – >10 >10 >10 >10 3 3 4 3
1O12 IgG1 κ + + + + + + – – >10 >10 >10 >10 1 1 12 1

























rPr D1 D2 D3 D4 D1 D2 D3 D4
106
1E23 IgG1 λ + + + + – – – + >10 >10 >10 >10 8 6 55 3
2F13 IgG1 κ + + + + + – + – >10 >10 >10 >10 5 5 3 1
1L21 IgG1 κ + + + + + + – – >10 >10 >10 >10 5 7 1 1
1M6.2 IgG1 κ + + + + + – + – >10 8.2 >10 >10 4 3 29 1
1H7.2 IgG1 λ + + + + – – – + >10 >10 >10 >10 11 9 30 4
2E14 IgG1 κ + + + + + – + – >10 >10 >10 >10 31 13 10 4
1K16.2 IgG1 λ + + + + + – + – >10 >10 >10 >10 8 35 19 3
1K4.2 IgG1 κ + + + + – – – + >10 >10 >10 >10 5 15 6 2
2H21 IgG1 λ + + + + – – – + >10 >10 >10 >10 21 4 18 4
2B17 IgG1 λ + + + + – – – + >10 >10 >10 >10 3 3 4 3
2G3 IgG1 λ + + + + – – – + >10 >10 >10 >10 22 4 47 8
2J9 IgG1 λ + + + + – – – + >10 >10 >10 >10 9 8 25 11
1G19 IgG1 κ + + + + + – + – >10 >10 >10 >10 4 10 4 2
1N21 IgG1 κ + + + + + + – – >10 >10 >10 >10 10 7 44 2
1I13.2 IgG1 λ + + + + – – – + >10 >10 >10 >10 8 15 16 8
1D8 IgG1 κ + + + + + – + – >10 >10 >10 >10 5 9 8 6
1A17 IgG1 κ + + + + – – – + >10 >10 >10 >10 118 60 47 4
1D6 IgG1 κ + + + + + – + – >10 >10 >10 >10 3 6 4 4
1N6 IgG1 κ + – – – + + – – >10 >10 >10 >10 5 0 1 1
2M23 IgG1 λ + + + + + + – – >10 >10 >10 >10 15 5 34 4
2I11 IgG1 λ + + + + – – – + >10 >10 >10 >10 24 6 26 5
2J21 IgG1 κ + + + + + – + – >10 >10 >10 >10 18 7 28 1
2I21 IgG1 λ + + + + + + – – >10 >10 >10 >10 14 7 4 1
2E19 IgG1 λ + + + + + – + – >10 >10 >10 >10 1 3 2 2
2I23 IgG3 λ + + + + + – + – >10 >10 >10 >10 5 1 1 1
2O19 IgG1 λ + + + + + + – – >10 >10 >10 >10 2 2 2 1
2J23 IgG1 κ + + + + + – + – >10 >10 >10 >10 25 6 7 3
2B20 IgG1 κ + + + + + – + – >10 >10 >10 >10 19 5 0 1
2D22.2 IgG1 λ + + + + + – + – >10 >10 >10 >10 10 6 1 2
GL10
2F17.2 IgG1 λ + + + + + – + – >10 >10 >10 >10 2 3 2 1
1H16.2 IgG1 κ + + + – – – – + >10 >10 >10 >10 1 5 3 2
1M4 IgG1 κ + + + + + – + – 0.56 0.27 5.4 2.3 6 1 56 1
1I3.2 IgG1 κ + + + + + – + – >10 >10 >10 >10 9 5 18 8
2H2 IgG1 κ + + + + – – – + >10 >10 >10 >10 6 9 15 1
GL24
2G19 IgG2 λ + + + – – – – + >10 >10 >10 >10 14 13 53 7
Abbreviations: DENV1, dengue virus serotype 1; IgG, immunoglobulin G; Neut50, concentration at which 50% of virus was neutralized; rE, recombinant E protein;
rEDI-II, recombinant E protein domain I-II; rEDIII, recombinant E protein domain III; rPr, recombinant premembrane protein.
a The Neut50, determined by enzyme-linked immunosorbent assay, is shown for each DENV serotype. A dash indicates a neut50 value of >10 µg/mL, neut50 values
between 1.0–10.0 µg/mL are shown, and neut50 values <0.5 µg/mL are in bold.
b Values were determined by antibody-dependent enhancement assay. Values indicating >25-fold enhancement are in bold.
Human mAbs From Dengue Vaccine Recipients • JID 2013:207 (15 June) • 1905
they target epitopes present only on the virion particle), that
appear to be the primary contributors to the neutralization ac-
tivity in human immune serum. In the present study, we
screened for virus-reactive antibodies, using purified whole
virus preparations expected to contain both immature and
mature virus particles and all of the virus structural proteins.
This approach allowed for the unbiased interrogation of B-cell
cultures and thus identified B cells secreting antibodies to
diverse domains of the E and prM proteins. However, given the
rarity of virion-only binding antibody-producing B cells in cir-
culation following infection or vaccination, this comprehensive
approach is not likely to isolate type-specific ultrapotent anti-
bodies, which compose <1% of induced antibodies. In this
study, as expected, virion-only binding antibodies were not iso-
lated from vaccinees or naturally infected subjects with the
panel of antibodies identified, since the panel contained 63 new
human mAbs. Likely, it would be necessary to generate thou-
sands of human mAbs to isolate a large panel of virion-only
binding or potently neutralizing antibodies from DENV-
immune subjects, since unbiased screening for mAbs reveals a
low frequency of such clones. This finding is not likely a techni-
cal problem with our study; rather, the rarity of neutralizing
clones appears to be the nature of the biology of the response.
The antigen specificity profiles of mAbs isolated from vacci-
nated and naturally infected individuals were remarkably
similar, despite significant differences in the interval since ex-
posure to antigen. Samples from vaccinated individuals were
obtained 1 month following a second dose of vaccine, while
samples from naturally infected individuals were obtained 2–15
years after recovery from infection. The similarity in this
memory B-cell response may reflect durability and suggests
that the response to vaccination is long-lived. We were unable
to test how the memory response to vaccination might mature
over time, because only 1 sample time point was used to gener-
ate mAbs from each subject.
In summary, the human B-cell response encoding DENV-
reactive antibodies is similar between live attenuated vaccina-
tion and natural infection. Most of the E protein– and prM
protein–specific antibodies in both groups exhibit ADE activity,
whereas only rare clones possessed strong neutralizing activity.
Figure 3. Dengue virus (DENV) serotype cross-reactivity profiles of purified human monoclonal antibodies (mAbs) generated following vaccination or
natural infection. Twenty-six purified human mAbs isolated after vaccination (left) or 37 mAbs recovered after natural infection (right) were tested by
enzyme-linked immunosorbent assay for binding to heterologous DENV. DENV-complex reactive, binding to all 4 DENV serotypes; DENV-subcomplex reac-
tive, binding to 2 or 3 DENV serotypes; DENV-serotype specific, binding only to DENV serotype 1.
Figure 4. Antigen specificity of purified human monoclonal antibodies (mAbs) generated following vaccination or natural infection. Twenty-six purified
human mAbs isolated after vaccination (left) and 37 mAbs isolated after natural infection (right) were tested for binding to recombinant prM (rPr), E protein
domain I-II (rEDI-II), or E protein domain III (rEDIII) constructs by enzyme-linked immunosorbent assay. Data are the percentage of total mAbs in each group.
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The studies suggest that live attenuated monovalent vaccination
does not induce a dramatically aberrant B-cell response that is
of concern, nor does it induce an unusually potent neutralizing
response that fundamentally differs from that following natural
infection. This is not entirely unexpected, since both groups ex-
perienced a DENV infection presenting wild-type structural
proteins, albeit with differing clinical features. Ideally, one
might like to manipulate the antigen exposure during vaccina-
tion, using antigen preparations designed to discourage the
dominant recognition of cross-reactive nonneutralizing sites by
the humoral immune response, while enhancing the induction
of protective neutralizing antibodies directed to epitopes that
are determinants of type-specific potent neutralizing responses.
The immune profiling described here provides molecular infor-
mation that could contribute to the rational design of dengue
vaccines that enhance the induction of protective antibodies
while reducing the potential for development of enhanced or
severe disease.
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